Cortexyme (CRTX) Appoints Marwan Sabbagh to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
March 15, 2022 8:00 AM EDTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimers and dementia care, to the companys Board of Directors.
Dr. Sabbaghs deep expertise in neurological diseases and extensive clinical development experience makes him a valuable addition to the Cortexyme Board of Directors, said Chris Lowe, Cortexymes interim chief executive officer. Cortexyme will benefit... More
